Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) Products under Development by Stage of Development | 7 | 1 |
| Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) Products under Development by Therapy Area | 8 | 1 |
| Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) Products under Development by Indication | 9 | 1 |
| Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) Products under Development by Companies | 12 | 2 |
| Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) Products under Development by Universities/Institutes | 14 | 2 |
| Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) Therapeutics Assessment | 16 | 4 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 1 |
| Assessment by Molecule Type | 19 | 1 |
| Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) Companies Involved in Therapeutics Development | 20 | 6 |
| Amgen Inc. | 20 | 1 |
| Handok Inc. | 21 | 1 |
| Hanmi Pharmaceuticals, Co. Ltd. | 22 | 1 |
| Merck &Co., Inc. | 23 | 1 |
| Novartis AG | 24 | 1 |
| Viking Therapeutics, Inc. | 25 | 1 |
| Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) Drug Profiles | 26 | 9 |
| BH-03004 Drug Profile | 26 | 1 |
| HL-5201 Drug Profile | 27 | 1 |
| KR-69530 Drug Profile | 28 | 1 |
| pradigastat sodium Drug Profile | 29 | 2 |
| Small Molecule 1 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type 2 Diabetes Drug Profile | 31 | 1 |
| Small Molecule 2 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type 2 Diabetes Drug Profile | 32 | 1 |
| Small Molecules to Inhibit DGAT-1 for Dyslipidemia and Obesity Drug Profile | 33 | 1 |
| Small Molecules to Inhibit DGAT1 Drug Profile | 34 | 1 |
| Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) Dormant Projects | 35 | 1 |
| Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) Discontinued Products | 36 | 2 |
| Appendix | 38 | 2 |
| Methodology | 38 | 1 |
| Coverage | 38 | 1 |
| Secondary Research | 38 | 1 |
| Primary Research | 38 | 1 |
| Expert Panel Validation | 38 | 1 |
| Contact Us | 38 | 1 |
| Disclaimer | 39 | 1 |